杨伟杰,赖荣芬,李岩,杜洋洋,洪晓丹
YANG Weijie,LAI Rongfen,LI Yan,DU Yangyang,HONG Xiaodan

• 1:惠州市中大惠亚医院药剂科

摘要(Abstract)：

目的考察临床药师在血液透析患者药物治疗管理中的作用。方法采用对照研究方法,研究临床药师参与58名血液透析患者的药物治疗管理半年前后血压、血糖、血脂、肾性贫血和钙磷代谢的达标率变化情况。结果临床药师参与血液透析患者的用药管理后,血压达标率由32. 76%上升至39. 65%。血糖达标率由64. 91%上升至71. 92%。血红蛋白达标率由15. 22%上升至30. 43%。全段甲状旁腺素达标率由22. 22%上升至26. 67%。血磷达标率由24. 56%上升至28. 07%。但血钙达标率由52. 63%下降至45. 61%,钙磷乘积达标率由49. 12%下降至40. 35%。干预前后患者的血压、血糖、血红蛋白、钙磷代谢达标率均无显著性差异。胆固醇、甘油三脂和低密度脂蛋白胆固醇的达标率持平。结论临床药师参与血液透析患者的用药管理能促进患者对血压、血糖、血脂、肾性贫血和钙磷代谢的控制,同时能有效延缓并发症的发展和提高患者的生活质量。
OBJECTIVE To investigate the role of clinical pharmacists in drug treatment management of hemodialysis patients.METHODS A controlled study was conducted to study the changes of blood pressure,blood glucose,blood lipid,renal anemia and calcium and phosphorus metabolism in 58 hemodialysis patient before and after six-month medication therapy management by clinical pharmacists. RESULTS After clinical pharmacists participated in the administration of hemodialysis patients,the blood pressure control rate increased from 32. 76% to 39. 65%. The blood glucose control rate increased from 64. 91% to 71. 92%. The hemoglobin control rates increased from 15. 22% to 30. 43%. The parathyroid hormone control rate increased from 22. 22% to 26. 67%. The blood phosphorus control rate increased from 24. 56% to 28. 07%. However,the blood calcium control rate decreased from 52. 63% to 45.61%,and the calcium phosphorus product control rate decreased from 49. 12% to 40. 35%. There was no significant difference in blood pressure,blood glucose,hemoglobin,calcium and phosphorus metabolism before and after treatment. The control rates of total cholesterol,triglycerides and LDL cholesterol remained the same. CONCLUSION The involvement of clinical pharmacists in medication management can promote the control of patients' blood pressure,blood glucose,blood lipid,renal anemia and calcium and phosphorus metabolism,and effectively delay the development of complications and improve the quality of life of patients

关键词(KeyWords)： 临床药师;血液透析;药物治疗管理;达标率
clinical pharmacist;hematodialysis;medication therapy management;control rates

Abstract:

Keywords:

基金项目(Foundation): 广东省医院药学研究基金(2019A25);; 2018年惠州市医疗卫生科技计划项目(2018Y291)

作者(Author): 杨伟杰,赖荣芬,李岩,杜洋洋,洪晓丹
YANG Weijie,LAI Rongfen,LI Yan,DU Yangyang,HONG Xiaodan

参考文献(References)：

• [1]安玉，蒋琦，刘志红．慢性肾脏病:全球肾脏健康状况及应对措施[J]．肾脏病与透析肾移植杂志，2018,27(1):61-64.
• [2]Webster A C,Nagler E V,Morton R L,et al. Chronic kidney disease[J]. The Lancet,2017,389(10075):1238-1252.
• [3]赵慧颖，黄雯，张国娟，等．各级医院非肾脏病科医生对慢性肾脏病知晓率的调查分析[J]．中国血液净化，2017,16(2):100-103.
• [4]肖月，隋宾艳，赵琨．我国终末期肾病现状及透析技术的应用，费用及支付情况分析[J]．中国卫生政策研究，2011,4(5):29-33.
• [5]中华医学会，中华医学杂志社，中华医学会全科医学分会，等．高血压基层诊疗指南(2019年)[J]．中华全科医师杂志，2019,18(4):301-313.
• [6]中华医学会，中华医学会杂志社，中华医学会全科医学分会，等．血脂异常基层诊疗指南(2019年)[J]．中华全科医师杂志，2019,18(5):406-416.
• [7]中华医学会肾脏病学分会肾性贫血诊断和治疗共识专家组．肾性贫血诊断与治疗中国专家共识(2018修订版)[J]．中华肾脏病杂志，2018,34(11):860-866.
• [8]Wald R,Tentori F,Tighiouart H,et al. Impact of the kidney disease outcomes quality initiative(KDOQI)clinical practice guidelines for bone metabolism and disease in a large dialysis network[J]. American journal of kidney diseases,2007,49(2):257-266.
• [9]李月红，窦红宇．慢性肾脏病患者血脂异常特点及治疗进展[J]．中华老年多器官疾病杂志，2015,14(7):556-560.
• [10]侯新艳，刘帝，刘烨歆，等．维持性血液透析患者贫血及相关因素分析[J]．临床肾脏病杂志，2016,16(12):718-722.
• [11]王雨涛，孙雪松，柳娟，等．碳酸钙治疗血透患者高磷血症的疗效观察[J]．临床医药文献电子杂志，2014,1(13):2340-2341.